Navigation Links
NicOx' Naproxcinod Phase 3 Results Presented at American College of Rheumatology
Date:11/12/2007

SOPHIA ANTIPOLIS, France, Nov. 12 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today announced that results from the first pivotal phase 3 trial for naproxcinod in patients with osteoarthritis of the knee (the 301 study) were presented on November 10, 2007 at the 71st annual meeting of the American College of Rheumatology (ACR), in Boston, Massachusetts (see NOTE). Naproxcinod is NicOx' lead investigational drug product and the first compound in the COX-Inhibiting Nitric Oxide Donator (CINOD) class. The presentation contained additional efficacy data to the top-line results announced in 2006 (see press release of October 27, 2006) which showed that naproxcinod met all three co-primary endpoints of the trial. The data showed that both doses of naproxcinod (750 mg and 375 mg bid) had superior efficacy to placebo at all time points (2, 6 and 13 weeks). This presentation also contained additional safety and tolerability information, including the gastro-intestinal adverse event rates and blood pressure measurements reported for each of the treatment groups.

Detailed clinical data from the 301 study were presented, including data for each of the three co-primary efficacy endpoints: WOMAC(TM) pain subscale, WOMAC(TM) function subscale and patients' overall rating of disease status. Each of the active treatments (naproxcinod 750 mg, naproxcinod 375 mg and naproxen 500 mg bid) were statistically significantly superior to placebo (p<=0.0002) at 2, 6 and 13 weeks. In addition, standard quality of life scores showed a functional improvement for both naproxcinod doses, as well as for the naproxen group.

At week 13, both doses of naproxcinod (750 mg and 375 mg bid) showed a slight decrease in systolic blood pressure in terms of the mean change from baseline compared to placebo (0.8 and 0.2 mmHg, respectively), while a 2 mmHg increase was observed for naproxen compared to placebo. Patients' blood pressure was measured by a health care professional using
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... BEVERLY HILLS, Calif. , Jan. 14, 2014 The Brandeis ... Los Angeles a premier and affordable laser tattoo ... treatment special. Dr. Brandeis, focus is in providing high quality cosmetic ... to all patients. " Southern California ...
(Date:1/14/2014)... Jan. 14, 2014 Animal Emergency Critical Care, a LifeCentre partner ... Virginia is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is ... husband, Dr. Cole Taylor , are avid scuba divers. "As ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
(Date:4/23/2014)... Effects of Midlife Occupational and Leisure Time Physical Activity ... physical activity in midlife increases the risk of mobility ... the risk. This is found in a study which ... The study was conducted at the Gerontology Research Center ... , Heavy physical labor is often repetitive, wears the ...
(Date:4/23/2014)... disease has been a rapidly evolving pursuit with ... crook in the research road, scientists have found ... associated with the disease. The report, which appears ... could have important implications for developing novel treatments. ... explain that for years, research has suggested a ...
(Date:4/22/2014)... decades researchers have characterized a set of clock genes ... all types of species, from flies to humans. Over ... surmise there are more. A team from the Perelman ... if big-data approaches could find them. , To ... PhD, professor of Pharmacology and first author Ron Anafi, ...
(Date:4/22/2014)... The risk of pregnancy among women using a ... more than 10 times greater over a 10-year period ... study by researchers at Yale University and UC Davis ... medical journal Contraception , the study found the ... marketed under the brand name Essure. , "This ...
(Date:4/22/2014)... NY, April 22, 2014Hemoglobin A1c is the standard measurement ... diabetes. Blood levels of A1c are typically measured every ... developed a data-based model that accurately estimates A1c using ... Diabetes Technology & Therapeutics ( DTT ), a ... article is available free on the DTT ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... Janssen-Cilag,EMEA, a division of Janssen Pharmaceutica ... received marketing authorisation in Finland and,Sweden for ... in men 18-64,years of age. These approvals ... authorisation procedure in seven European Union countries: ...
... Varian, Inc.,(NasdaqGS: VARI) today reported that its Board of ... Executive Officer, as Chairman,of the Board. He replaces Allen ... director term at the annual meeting of stockholders held on,February ... Executive,Officer. , "We were very fortunate ...
... in 3 will do so for Fido, if not for ... who won,t kick the habit for their own health will ... "We wanted to determine whether pet owners who learned that ... behavior," said Sharon Milberger, an epidemiologist at the Henry Ford ...
... frail for open-heart surgery CHICAGO, Feb 9 ... of his heart valve -- hardening that is formally ... out of the question. He,d already survived quadruple ... a century, Lafferty wasn,t a good candidate for heart ...
... LCA-Vision Full Value,Committee announced today that it has ... solicitation materials and is commencing,distribution of those soliciting ... LCAV ) ("LCAV") to solicit consents to replace ... five highly qualified nominees. The Full,Value Committee,s ...
... Nationwide tour to impact the lives of one million ... economic timesPLEASANTON, Calif., Feb. 9 Shaklee Corporation Chairman ... to promote an opportunity that offers economic support to ... to New York City, NY on Feb. 10."Families are ...
Cached Medicine News:Health News:Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden 2Health News:Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden 3Health News:Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden 4Health News:Garry W. Rogerson Elected Chairman of the Board of Varian, Inc. 2Health News:Smokers Will Stop for Their Pet's Sake 2Health News:Diseased Heart Valve Replaced Through Small Chest Incision 2Health News:Diseased Heart Valve Replaced Through Small Chest Incision 3Health News:Diseased Heart Valve Replaced Through Small Chest Incision 4Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 2Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 3Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 4Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 5Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 6Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 7Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 8Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 9Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 10Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 11Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 12Health News:Shaklee Hits the Road with its Infinite Possibilities Tour in New York, NY 2
... digital x-ray detectors from KUBTEC represents a ... 12 to 16 bit digital interface. The ... array sensor with pixel spacing down to ... low x-ray energies (10-50 kV) and an ...
... a breakthrough in specimen radiography. The XPERT represents ... 65,536 shades of gray in every digital x-ray ... changes in density that heretofore were lost to ... from 2 x 2 to 8 x 8 ...
The Triage Profiler Shortness of Breath Panel provides rapid risk assessment and differential diagnosis of patients presenting to the emergency department with shortness of breath and risk assessment...
... in the field of Urodynamics, Albyn Medical recognised ... new chair is manufactured from the highest quality ... can be improved considerably if the patient is ... this aspect was given a high priority in ...
Medicine Products: